Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Arthritis Research & Therapy|June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studiesMark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
Archives of Internal Medicine|January 26, 2005
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitusJames R Sowers, William B White, Bertram Pitt, et al.
The Journal of Rheumatology|December 16, 2020
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II StudyMark C Genovese, Alberto Spindler, Akira Sagawa, et al.
Rheumatology and Therapy|October 31, 2023
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational StudyAnisha B Dua, Kerri Ford, Stefano Fiore, et al.
Rheumatology (Oxford, England)|April 4, 2022
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled studyElizabeth Price, Michele Bombardieri, Alan Kivitz, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 13, 2024
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA studySławomir Jeka, Eva Dokoupilová, Alan Kivitz, et al.
Rheumatology and Therapy|May 18, 2023
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension StudyAlan Kivitz, Alvin F Wells, Juan I Vargas, et al.
Rheumatology (Oxford, England)|July 24, 2020
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trialJosef S Smolen, Stanley B Cohen, Hans-Peter Tony, et al.
Rheumatology (Oxford, England)|September 12, 2018
Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 studySteven J Russell, Robert Sala, Philip G Conaghan, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialGerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
Pageof 10